- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00399503
Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack
Risk Estimation Following Infarction Noninvasive Evaluation (REFINE)
Study Overview
Status
Conditions
Detailed Description
Background. Sudden cardiac death (SCD) kills >450,000 North Americans each year. Patients with a history of myocardial infarction (MI) are at particular risk. Concurrent alterations in myocardial structure & autonomic tone appear important for the development of the arrhythmias leading to SCD.
Given the grave consequences of SCD, an ideal testing procedure should identify most of those at risk (sensitive) & correctly classify risk (accurate). Since >90% of patients who suffer serious arrhythmias post-MI have at least mild left ventricular (LV) dysfunction (ejection fraction [EF] <0.50) this is an optimal group to study.
While noninvasive tests have been developed to estimate SCD risk, prior approaches have failed to: 1) identify the majority of patients at risk for serious arrhythmias (insensitive), 2) evaluate temporal changes in parameters, 3) identify the optimal timing for risk assessment post-MI, & 4) develop a widely-applicable screening tool. This has resulted in a failure to delivery effective therapies (e.g., defibrillator) in a cost-effective manner.
Hypotheses. Primary: Concurrent evaluation of electrical structure & autonomic tone will accurately identify most post-MI patients at risk of serious arrhythmic events. Secondary: 1) assessment later (16 weeks) provides more prognostic information than assessment early post-MI (4 weeks), 2) a single multi-parameter test procedure can be developed, and 3) individually, repolarization alternans provides the most prognostic information.
Methods. 350 persons with a recent MI (<31 days) & EF <0.50 will undergo testing early (4 weeks), intermediate (8 weeks) & late (16 weeks) post-MI.
Four techniques assess cardiac structure (spectral T-wave alternans [TWA], modified moving average TWA; signal-averaged [SA] ECG) & nuclear ejection fraction. Three others evaluate autonomic tone (baroreceptor sensitivity [BRS], heart rate variability [HRV], and Heart Rate Turbulence [HRT]).
Data Collection & Outcomes. Patients will be recruited over 24 months & followed biannually for four years. Committee (blinded) endpoint classification & central laboratory data analysis will be utilized. A composite of resuscitated cardiac arrest and cardiac mortality is the primary outcome. The components (resuscitated / non-resuscitated cardiac arrest and cardiac death) are secondary outcomes.
Statistical Aspects & Sample Size. Standard methods of description & analysis will be used. The capacity to accurately identify most patients at risk for serious arrhythmias will be evaluated using Cox multivariate models. The primary model will include age, sex, EF at 8 wks & important baseline medication use.
Since multivariate modeling requires lower (more sensitive) dichotomy limits the following will be used: spectral TWA positivity will be defined as a non-negative test. SA-ECG QRS width >104 msec will be labeled as abnormal. For HRV, SDNN values <105 msec will be considered abnormal. For BRS, values <6.1 msec per mmHg will indicate impairment. For HRT abnormalities in T-onset & / or T-slope will be considered abnormal. Receiver operating characteristic curves will be used to identify a cut-point for modified moving average TWA.
Assuming a 5 year 20% rate of the composite arrhythmias in patients with positive test results, we have 85% power to detect a 2.5-fold higher risk in patients with abnormalities than those without these abnormalities.
Relevance. This is the first large prospective study to evaluate the utility of concurrent structural & autonomic tone assessment in predicting the development of serious arrhythmias after an MI.
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N1
- Foothills Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed MI <31 days, based upon elevated cardiac-specific CK (total CK-MB mass >7ng/mL or CK-MB/total CK ≥ 2.5%) or troponin-T (> 0.1 ng/ml)144) plus
- clinical symptoms or ECG evidence of myocardial injury (ST deviation ≥ 1 mm in 2, contiguous leads or new/previously undocumented Q waves)144, &
- left ventricular ejection fraction ≤ 0.40 within 48 hrs or ≤ 0.50 beyond 48 hrs of MI using (echocardiography, radionuclide or contrast angiography) &
- Sinus rhythm at the time of enrollment.
Exclusion Criteria:
- Geographic isolation or inability to return for follow-up,
- Comorbid illness likely to cause death within 24 months,
- Inability to complete a submaximal exercise test (e.g., urgent CABG),
- Class I indication for a defibrillator (e.g., VF or sustained VT > 48 hours of index MI), or
- Lack of written informed consent
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Derek V Exner, MD, MPH, Libin Cardiovascular Institute of Alberta, University of Calgary
Publications and helpful links
General Publications
- Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, Van Schaik A, Mitchell RT, Shibata MA, Gulamhussein S, McMeekin J, Tymchak W, Schnell G, Gillis AM, Sheldon RS, Fick GH, Duff HJ; REFINE Investigators. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol. 2007 Dec 11;50(24):2275-84. doi: 10.1016/j.jacc.2007.08.042. Epub 2007 Nov 26.
- Slawnych MP, Nieminen T, Kahonen M, Kavanagh KM, Lehtimaki T, Ramadan D, Viik J, Aggarwal SG, Lehtinen R, Ellis L, Nikus K, Exner DV; REFINE (Risk Estimation Following Infarction Noninvasive Evaluation); FINCAVAS (Finnish Cardiovascular Study) Investigators. Post-exercise assessment of cardiac repolarization alternans in patients with coronary artery disease using the modified moving average method. J Am Coll Cardiol. 2009 Mar 31;53(13):1130-7. doi: 10.1016/j.jacc.2008.12.026.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIHR 73-1518
- HSFA 73-1220
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Beijing Northland Biotech. Co., Ltd.Not yet recruitingAcute Myocardial Infarction (AMI) | Acute Myocardial Infarction of Anterior Wall | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction With ST Segment Elevation | Acute Myocardial Infarction of Left VentricleChina
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SAWithdrawn
-
Samsung Medical CenterThe Korean Society of CardiologyNot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Harbin Medical UniversityNot yet recruitingNon-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)Acute Myocardial Infarction (AMI) | ST-Segment Elevation Myocardial Infarction(STEMI) | Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)China
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationCompletedST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionUnited States, Spain, Netherlands, Canada, Australia, Serbia, Egypt, Switzerland, Hungary, United Kingdom, France, Czechia, Nepal, North Macedonia
-
Chonnam National University HospitalNot yet recruitingMyocardial Infarction (MI) | AF - Atrial Fibrillation | NSTEMI - Non-ST-Segment Elevation Myocardial Infarction | ST-Segment Elevation Myocardial Infarction(STEMI)South Korea
Clinical Trials on Spectral T Wave Alternans
-
Loma Linda UniversityCompletedChest Pain | Acute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
Creighton UniversityCompletedMyocardial Infarction | ArrhythmiasUnited States
-
Abbott Medical DevicesMetroHealth Medical Center; Cambridge Heart Inc.CompletedIschemic Cardiomyopathy | LV Dysfunction
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedMyocardial Infarction | Ischemic Cardiomyopathy | Arrhythmia, VentricularUnited States
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedMyocardial Infarction | Ischemic Cardiomyopathy | Arrhythmia, VentricularUnited States
-
Suzhou Zhonghui Medical Technology Co., Ltd.Not yet recruitingModerate to Severe Calcified Coronary Artery Stenosis
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCompletedErectile DysfunctionUnited States
-
Clinical Research Consultants, Inc.Alcon Research; WaveLight AGCompletedMyopia | HyperopiaUnited States
-
Deutsches Herzzentrum MuenchenCompletedDefibrillation Testing - ICD Therapy OptimisationGermany
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedRelapsing Remitting Multiple Sclerosis